Prakash Chinnaiyan
Experienced in Pulmonary Arteriovenous Malformation (PAVM)

Dr. Prakash Chinnaiyan

Radiation Oncology
3577 West 13 Mile Road, Suite Ll, 
Royal Oak, MI 
On Staff At
Accepting New Patients
25 Years of Experience
Experienced in Pulmonary Arteriovenous Malformation (PAVM)
3577 West 13 Mile Road, Suite Ll, 
Royal Oak, MI 
OverviewInsuranceLocationsClinical Research

Overview

Prakash Chinnaiyan is a Radiation Oncologist in Royal Oak, Michigan. Dr. Chinnaiyan has been practicing medicine for over 25 years and is rated as an Experienced provider by MediFind in the treatment of Pulmonary Arteriovenous Malformation (PAVM). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Gamma Knife Radiosurgery. Dr. Chinnaiyan is currently accepting new patients.

His clinical research consists of co-authoring 54 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Wayne State University School Of Medicine, 2000
Residency
University of WI Hospital & Clinics
Specialties
Radiation Oncology
Licenses
Therapeutic Radiology in WI
Board Certifications
American Board Of Radiology
Hospital Affiliations
Corewell Health Trenton Hospital
Corewell Health Beaumont Grosse Pointe Hospital
Corewell Health Taylor Hospital
Corewell Health William Beaumont University Hospital
Corewell Health Beaumont Troy Hospital
Corewell Health Wayne Hospital
Corewell Health Dearborn Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
AmeriHealth
  • EPO
  • HMO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 11 Less Insurance Carriers -

Locations

Rose Cancer Treatment Center
3577 West 13 Mile Road, Suite Ll, Royal Oak, MI 48073
Other Locations
Corewell Health William Beaumont University Hospital - Radiation Oncology
3577 West 13 Mile Road, Royal Oak, MI 48073

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
Enrollment Status: Terminated
Publish Date: February 04, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 1
View 1 Less Clinical Trial

54 Total Publications

Enhanced lipid metabolism serves as a metabolic vulnerability to a polyunsaturated fatty acid (PUFA)-rich diet in glioblastoma.
Enhanced lipid metabolism serves as a metabolic vulnerability to a polyunsaturated fatty acid (PUFA)-rich diet in glioblastoma.
Journal: Research square
Published: July 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chinnaiyan's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 9 Advanced Conditions
View All 79 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile